Skip to main content

Solomons Neil's Form 4 filing

Aurinia Pharmaceuticals Inc. (AUPH) · filed Sep 14, 2021

Accession no.
0001628280-21-018594
Filed
Sep 14, 2021
Trade date
Sep 10-13, 2021
Filing delay
4 days
Rule 10b5-1 plan
Not on the form (before 2023)

This filing lists 2 non-derivative transactions and 1 derivative transaction. Open-market sales total $2.98M. It was filed 4 days after the trade.

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
OwnerRelationship to the company
Solomons NeilCIK 0001837720Officer (Chief Medical Officer)

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade dateSecurityTransactionSharesPriceValueShares afterOwnershipFlags
Sep 13, 2021Common SharesMOption exerciseAcquired+150,000$3.20F1+$480,000287,299Direct
Sep 10, 2021Common SharesSSaleDisposed−150,000$19.84F3−$2,976,000137,299Direct

Derivative securities (Table II)

Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.

Derivative transactions
Trade dateSecurityTransactionUnderlying sharesUnit priceValueHeld afterOwnershipFlags
Sep 13, 2021Common StockMOption exerciseDisposed−150,000$0.00$02,000Direct

Footnotes and remarks

Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.

F1

Converted to U.S. dollars based on the average daily exchange rate of the Bank of Canada reported on the grant date.

Referenced by the price of 1 transaction in Table I.

F3

The price in column 4 is a weighted average price. These shares were purchased in multiple transactions ranging from $19.77 to $19.89, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range.

Referenced by the price of 1 transaction in Table I.

Read the full filing on SEC EDGAR (opens in a new tab)